tradingkey.logo

MaxCyte Inc

MXCT
0.808USD
0.0000.00%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
86.17MCap. mercado
PérdidaP/E TTM

Más Datos de MaxCyte Inc Compañía

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Información de MaxCyte Inc

Símbolo de cotizaciónMXCT
Nombre de la empresaMaxCyte Inc
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)
Número de empleados114
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 29
Dirección9713 Key West Avenue,
CiudadROCKVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal20850
Teléfono13015175556
Sitio Webhttps://www.maxcyte.com/
Símbolo de cotizaciónMXCT
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMasoud (Maher)

Ejecutivos de MaxCyte Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+18526.00%
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Sandoval
Mr. David Sandoval
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+100000.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+80000.00%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75000.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+29210.00%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+29210.00%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
+50000.00%

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%
Por regiónUSD
Nombre
Ganancia
Proporción
Inside the United States
3.84M
56.17%
Outside the United States
2.99M
43.83%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
3.95M
57.89%
Product
3.95M
57.89%
Licenses
2.23M
32.60%
other
650.00K
9.52%

Estadísticas de accionistas

Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Otro
64.18%
Accionistas
Accionistas
Proporción
Cadian Capital Management LP
7.71%
Capricorn Fund Managers Ltd
7.69%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.19%
Otro
64.18%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
29.83%
Investment Advisor/Hedge Fund
24.34%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
Otro
15.93%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
282
79.67M
74.69%
-13.89M
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Cadian Capital Management LP
8.23M
7.71%
-686.87K
-7.71%
Sep 30, 2025
Mirabella Financial Services LLP
8.20M
7.69%
+1.60M
+24.24%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.04M
7.54%
-168.77K
-2.06%
Sep 30, 2025
The Vanguard Group, Inc.
5.59M
5.24%
-13.59K
-0.24%
Sep 30, 2025
River Global Investors LLP
5.50M
5.15%
+2.24M
+68.99%
Oct 23, 2025
Vitruvian Partners LLP
5.04M
4.73%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.25M
3.98%
+12.10K
+0.29%
Sep 30, 2025
Mudita Advisors LLP
3.37M
3.16%
--
--
Sep 30, 2025
AXA Investment Managers UK Ltd.
2.77M
2.6%
+571.18K
+25.93%
Sep 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.6%
iShares Micro-Cap ETF
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
iShares Biotechnology ETF
Proporción0.01%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI